Table 4.

Patient and disease characteristics of those whose metastatic sample was assessed.

Characteristics	Non-adjuvant anti-PD-1-based therapy, n = 101
Matched with primary, n (%)
Matched	31 (31)
Not matched	70 (69)
Centre, n (%)
Dresden	4 (4)
St. Gallen	12 (12)
Tuebingen	85 (84)
eTILs (%), median [IQR]	13 [8–21]
Sex, n (%)
Female	37 (37)
Male	64 (63)
Age at therapy (yrs), median [IQR]	68 [59–77]
Age at therapy (yrs), n (%)
≤65	41 (40.6)
>65	60 (59.4)
Therapy, n (%)
Anti-PD-based monotherapy	59 (59)
Nivolumab + Ipilimumab	42 (41)
Stage at therapy, n (%)
IIIA	1 (1.0)
IIIB	1 (1.0)
IIIC	7 (6.9)
IIID	–
IV-M1a	10 (9.9)
IV-M1b	18 (18)
IV-M1c	46 (46)
IV-M1d	18 (18)
BRAF mutation, n (%)
Mutated	27 (27)
Wt	72 (71)
Unknown	2 (2.0)
Brain Metastases, n (%)
Metastases	18 (18)
No metastases	83 (82)
LDH at therapy start (U/l), median [IQR]	223 [184–300]
LDH at therapy start (U/l), n (%)
≤250	20 (62.5)
>250	12 (37.5)

Values are reported as counts (n) and percentages (%) for discrete values and as a median and interquartile range [IQR] for continuous values.